Editas Medicine, Inc.

Editas Medicine, Inc. is a leading biotechnology firm focused on clinical-stage genome editing, with a primary mission to pioneer groundbreaking genetic therapies designed to address a wide array of severe medical conditions. The company leverages a unique, in-house developed gene editing platform that utilizes cutting-edge CRISPR technology. Editas's pipeline features several promising candidates, including EDIT-101, which is currently undergoing Phase 1/2 clinical trials for Leber Congenital Amaurosis 10, a genetic disorder causing inherited childhood blindness. Additionally, EDIT-102 is under development to tackle Usher Syndrome 2A, a form of retinitis pigmentosa accompanied by hearing impairment, as well as autosomal dominant retinitis pigmentosa, a progressive retinal degeneration. Its portfolio also includes EDIT-301, designed to treat sickle cell disease and transfusion-dependent beta-thalassemia. Furthermore, Editas is advancing gene-edited Natural Killer (NK) cell therapies for solid tumor cancers, alpha-beta T cell therapies for various malignancies, and gamma delta T cell treatments, also targeting cancer. An early-stage research initiative is also underway to discover a therapeutic solution for a neurological disorder. The company has forged strategic partnerships to broaden its research and development capabilities. These include a collaboration with Juno Therapeutics, Inc. for engineered T cells in oncology; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited focused on discovering, developing, and marketing gene-edited treatments for a range of eye conditions; and research collaborations with Asklepios BioPharmaceutical, Inc. (also referred to as AskBio) to develop therapies for neurological diseases. Originally established as Gengine, Inc., the company rebranded to Editas Medicine, Inc. in November 2013, the same year it was incorporated. Its operations are based in Cambridge, Massachusetts.